Table 2.

Univariate analysis of patients’ clinical characteristics

Variable	Total (n = 272)	Stroke/TIA (n = 136)	No Stroke/TIA (n = 136)	p-value
Cancer Stage
Localized	59 (22%)	26 (19%)	33 (24%)	.320
Regional	49 (18%)	21 (15%)	28 (21%)
Distant	125 (46%)	69 (51%)	56 (41%)
Unstageable	39 (14%)	20 (15%)	19 (14%)
Cancer-Specific Management
Active Cancer Treatment at The Time of Event (Stroke/TIA)	94 (35%)	60 (44%)	34 (25%)	.002
History of Chemotherapy	161 (59%)	83 (61%)	78 (57%)	.600
History of Hormonal Therapy	32 (12%)	13 (10%)	19 (14%)	.140
History of Radiotherapy	108 (40%)	56 (41%)	52 (38%)	.670
History of Cancer-Related Surgery	125/ 266 (47%)	57 (42%)	68/ 130 (52%)	.070
Atrial Fibrillation (New onset AF or baseline AF)	25 (9%)	19 (14%)	6 (4%)	.007
Comorbidities
Any	246 (90%)	131 (96%)	115 (85%)	.002
Hypertension	158 (58%)	88 (65%)	70 (52%)	.030
Diabetes Mellitus	111 (41%)	64 (47%)	47 (35%)	.040
Smoking	Smoker = 88 (32%) Ex-smoker = 43 (16%)	Smoker = 45 (33%) Ex-Smoker = 22 (16%)	Smoker = 43 (32%) Ex-smoker = 21 (15%)	.950
Dyslipidemia	68 (25%)	46 (34%)	22 (16%)	<.001
Renal Disease	56 (21%)	40 (29%)	16 (12%)	<.001
Coronary Artery Disease	52 (19%)	34 (25%)	18 (13%)	.020
Previous Ischemic Stroke (Before Cancer Diagnosis)	43 (16%)	39 (29%)	4 (3%)	<.001
Vascular Disease	39 (14%)	25 (18%)	14 (10%)	.080
Hypothyroidism	28 (10%)	16 (12%)	12 (9%)	.560
Congestive Heart Failure	13 (4%)	11 (8%)	2 (2%)	.020
CHA2DS2-VASc (groups)
Male < 2	105 (39%)	40 (29%)	65 (48%)	<.001
Female < 3
Male >= 2	167 (61%)	96 (71%)	71 (52%)
Female >= 3
HAS-BLED (groups)
< 3	180 (66%)	75 (55%)	105 (77%)	< .001
>= 3	92 (34%)	61 (45%)	31 (23%)
Anticoagulation Therapy	39 (14%)	24 (18%)	15 (11%)	.190
Antiplatelet Therapy	68 (25%)	39 (29%)	29 (21%)	.170
Death (at the time of study conclusion)	148 (54%)	103 (76%)	45 (33%)	< .001